Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

Akeso

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Solid Tumor, Adult

Treatments

Drug: AK119

Drug: AK104

Study type

Interventional

Funder types

Industry

Identifiers

NCT05559541

AK119-104

Details and patient eligibility

About

This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.

Enrollment

102 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects must sign the written informed consent form (ICF) voluntarily.
Age ≥ 18 years.
Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 to1.
Life expectancy ≥12 weeks.
Subjects must have histologically or cytologically confirmed advanced solid tumor that is refractory or relapsed to the current standard therapies, or for which no effective standard therapy is available.
Subjects must have evaluable lesions according to RECIST v1.1.
Subjects must have adequate organ function.
Female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective barrier methods of contraception during the study and for 120 days after last dose of study drug.

Exclusion criteria

Prior malignancy active within the previous 3 years except for the locally curable cancers that have been apparently cured.
Being involved in another clinical study, except for observational clinical studies or follow-up period of interventional studies.
Have exposed to other products targeting T cell costimulation or immune checkpoint pathway excepts for PD-1/PD-L1 inhibitor.
Anticancer therapy (e.g., chemotherapy, radiotherapy, etc.) within 4 weeks prior to the first dose of investigational product; Anticancer small-molecule targeted agent (e.g., tyrosine kinase inhibitor) within 2 weeks prior to the first dose of investigational product.
Subjects with spinal cord compression or active brain metastases, except for subjects with untreated and asymptomatic brain metastases or with stable brain metastases after treatment.
Subjects with pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
Subjects whose imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the study.
Toxicities of prior anticancer therapy have not resolved to ≤ Grade 1 (NCI-CTCAE version 5.0).
Patients with clinically significant cardio-cerebrovascular or venous thromboembolic disease.
Active autoimmune diseases or history of autoimmune diseases that may relapse.
History of interstitial lung disease or noninfectious pneumonitis.
Major surgery or trauma within 4 weeks prior to first dose of investigational product. Unhealed wound, ulcer or fracture within 4 weeks prior to first dose of investigational product.
Any condition that required systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of investigational product.
Receipt of live attenuated vaccines within 4 weeks prior to the first dose of investigational product.
Previous history of severe hypersensitivity reactions to other monoclonal antibodies.
Patients are pregnant or breastfeeding, or plan to breastfeed during the study.
Previous organ transplantation or allogeneic hematopoietic stem cell transplantation.
Any other conditions that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.